SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJpel Priv Eqty Regulatory News (JPEL)

Share Price Information for Jpel Priv Eqty (JPEL)

Share Price is delayed by 15 minutes
Get Live Data
1.24    0.00 (0.00%)
Bid:
1.20
Ask:
1.28
Spread: 0.08 (6.667%)
Market Cap: $21.21m
JPEL Live PriceLast checked at - London Stock Exchange

Intraday Jpel Priv Eqty Share Chart

Partial Exit

22 May 2014 07:00

RNS Number : 7443H
J.P. Morgan Private Equity Ltd
22 May 2014
 

J.P. Morgan Private Equity Limited

Carinthia House

9-12 The Grange

St Peter Port

Guernsey GY1 4BF

www.jpelonline.com

 

 

PARTIAL EXIT - Deutsche Annington Immobilien Group ("DAIG")

 

* * *

 

· JPEL PARTICIPATED ALONGSIDE OTHER INVESTORS IN A PLACING AT 19.50 EUROS PER SHARE

· RECEIVED APPROXIMATELY EURO 11.8 million in Cash proceeds or 25% of JPEL's POSITION IN DAIG

· RECEIVED an IN-KIND DISTRIBUTION of DAIG ordinary shares REMAINING 75% of JPEL's POSITION IN DAIG

· BASED ON A 19.50 EURO PER SHARE VALUE, JPEL's INVESTMENT IN TFDA HAS GENERATED APPROXIMATELY 2.76x JPEL's COST AND an irr of 25.6%

* * *

 

GUERNSEY, 22 MAY 2014

 

J.P. Morgan Private Equity Limited ("JPEL" or the "Company") is pleased to announce that, on 20 May 2014, the Company, through its investment in Terra Firma Deutsche Annington ("TFDA") participated alongside Terra Firma and several other investors in a 30 million share placing of Deutsche Annington Immobilien Group ("DAIG") at 19.50 Euros per share.

 

In connection with the placing, JPEL received:

· Cash proceeds of approximately Euro 11.8 million, representing 25% of JPEL's position in DAIG; and

· In-kind distribution of DAIG shares representing the remaining 75% of JPEL's position.

 

The distribution is net of all carried interest. JPEL will not pay any carried interest or management fees on its direct investment in DAIG going forward.

 

DAIG is JPEL's largest underlying company investment as at 31 March 2014.

 

JPEL initially gained exposure to DAIG in 2006 through a EUR 1.4 million investment in TFDA. In 2008, JPEL purchased a larger investment in the same co-investment vehicle at a substantial discount to the prevailing NAV at that time. Based on a 19.50 Euro per share value, JPEL's investment in TFDA has generated approximately 2.76x JPEL's cost and a 25.6% IRR.

 

JPEL's investment cost in DAIG is estimated to be below 8 Euros per share.

 

DAIG is Germany's largest residential real estate company with approximately 174,300 residential units of its own and 26,800 apartments managed for other owners as well as approximately 3,000 employees.

 

Pro forma for this partial realization, based on the most recent available balance sheet data for JPEL at 31 March 2014, JPEL would have net leverage* drawn under its credit facility of approximately $2.1 million. This is after JPEL invested approximately $50 million in 4 investments. Including the 2015 and 2017 ZDPs, JPEL's current pro forma net debt (including ZDPs)** is approximately 23% of total assets.

 

* Net leverage refers to total debt drawn under JPEL's credit facility less cash.* Net debt is defined as total debt drawn under JPEL's credit facility less cash plus accreted value of the 2015 and 2017 ZDP Shares.

 

* * *

 

For further information please contact:

 

J.P. Morgan Private Equity Limited

Greg Getschow

+1 212 648 1150

Gregory.Getschow@jpmorgan.com

 

Rosemary DeRise / Samantha Ladd

+1 212 648 2980 / +1 212 648 2982

Rosemary.DeRise@jpmorgan.com / Samantha.Ladd@jpmorgan.com

 

 

 

About J.P. Morgan Private Equity Limited

 

J.P. Morgan Private Equity Limited ("JPEL" or the "Company") is a Guernsey registered and incorporated, London Stock Exchange-listed, closed-ended investment company (LSE: JPEL, JPZZ, JPSZ). The Company's capital structure consists of three classes of shares: US$ Equity Shares and two classes of Zero Dividend Preference Shares due 2015 and 2017, respectively.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKSFAENLEFF
Date   Source Headline
2nd Jun 20269:29 amRNSNet Asset Value - March 2026
23rd Apr 20267:00 amRNSJoint Broker Appointment
14th Apr 20267:00 amRNSAppointment of Directors
6th Mar 20265:59 pmRNSHalf-year Financial Report - December 2025
14th Jan 20269:53 amRNSCOMPLETION OF THIRTEENTH MANDATORY REDEMPTION
29th Dec 20253:18 pmRNSTHIRTEENTH MANDATORY REDEMPTION
19th Dec 20255:53 pmRNSNet Asset Value September 2025
2nd Dec 20254:44 pmRNS2025 AGM Results Statement
10th Nov 202512:19 pmRNS2025 AGM Circular Statement
5th Nov 20254:07 pmRNSHolding(s) in Company
3rd Nov 20254:30 pmRNSHolding(s) in Company
3rd Nov 20254:11 pmRNSHolding(s) in Company
30th Oct 20257:00 amRNSAnnual Financial Report 2025
22nd Jul 20257:00 amRNSAppointed Sole Corp. Broker & Financial Adviser
10th Jun 20254:47 pmRNSNet Asset Value - March 2025
1st May 20256:11 pmRNSHolding(s) in Company
18th Mar 20255:04 pmRNSHalf-year Report - December 2024
3rd Dec 20242:30 pmRNSNet Asset Value September 2024
27th Nov 20245:16 pmRNS2024 AGM Results
6th Nov 20247:00 amRNS2024 AGM Circular
25th Oct 20247:00 amRNSPortfolio Update
25th Oct 20247:00 amRNSAnnual Financial Report - 2024
5th Jun 20247:00 amRNSNet Asset Value - March 2024
23rd Apr 20245:18 pmRNSDirector Declaration
15th Mar 20246:15 pmRNSNet Asset Value - December 2023
15th Mar 20246:03 pmRNSHalf-year Report - December 2023
15th Mar 20243:50 pmRNSHalf-year Report - 2023
6th Dec 20235:36 pmRNSDirector Declaration
6th Dec 20235:33 pmRNSAGM RESULTS 2023
9th Nov 202311:56 amRNS2023 AGM CIRCULAR
8th Nov 20237:00 amRNSCompletion of Twelfth Mandatory Redemption
24th Oct 20237:00 amRNSTwelfth Mandatory Redemption & Shareholder Update
20th Oct 202310:28 amRNSNet Asset Value - September 2023
21st Sep 20235:33 pmRNSNet Asset Value(s) - June 2023
21st Jun 20233:36 pmRNSDirectorate Change
12th May 20231:46 pmRNSNet Asset Value(s) - March 2023
28th Mar 20233:32 pmRNSHalf-year Report - 31 December 2022
14th Mar 20234:35 pmRNSPrice Monitoring Extension
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 202311:05 amRNSSecond Price Monitoring Extn
14th Mar 202311:00 amRNSPrice Monitoring Extension
14th Mar 20239:05 amRNSSecond Price Monitoring Extn
14th Mar 20239:00 amRNSPrice Monitoring Extension
24th Feb 20234:22 pmRNSNet Asset Value(s) - December 2022
13th Feb 20234:51 pmRNSDirector Declaration
22nd Dec 20227:00 amRNSCompletion of Eleventh Mandatory Redemption
14th Dec 20227:00 amRNSELEVENTH MANDATORY REDEMPTION & SHAREHOLDER UPDATE
13th Dec 20225:09 pmRNSDirectorate Change
29th Nov 20224:33 pmRNSAGM Results 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.